Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Study of VLA1553 Safety & Immunogenicity in Healthy Children Aged 1–11 Years
Details : Ixchiq (Chikungunya Vaccine, Live) is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Ixchiq
Product Type : Vaccine
Upfront Cash : Inapplicable
August 20, 2025
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2021
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Valneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Valneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VLA1553 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chikungunya Fever.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable